Patents Assigned to Palatin Technologies, Inc.
  • Use of bremelanotide in patients with controlled hypertension
    Patent number: 11590209
    Abstract: The present invention relates to formulations and methods for treatment of sexual dysfunction in females diagnosed with both sexual dysfunction and controlled hypertension.
    Type: Grant
    Filed: January 21, 2021
    Date of Patent: February 28, 2023
    Assignee: Palatin Technologies, Inc.
    Inventors: Julie Krop, Laura Ann Williams
  • Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications
    Publication number: 20230040236
    Abstract: Melanocortin receptor-specific cyclic peptide or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions or formulations and methods of preventing, ameliorating or treating melanocortin receptor-medicated diseases, indications, conditions and syndromes, including ocular indications, utilizing the cyclic peptide of the foregoing formula.
    Type: Application
    Filed: July 11, 2022
    Publication date: February 9, 2023
    Applicant: PALATIN TECHNOLOGIES, INC.
    Inventors: Wei YANG, John H. DODD, Axel METZGER
  • Reverse Amide-Linked Melanocortin Receptor-Specific Cyclic Peptides
    Publication number: 20220363719
    Abstract: Melanocortin receptor-specific cyclic peptides of the formula where Xaa1, R1, R2, R3, R4, R7, R8, R9, R10, t, x and y are as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes utilizing melanocortin receptor-specific cyclic peptides of formula I.
    Type: Application
    Filed: July 12, 2022
    Publication date: November 17, 2022
    Applicant: PALATIN TECHNOLOGIES, INC.
    Inventors: Wei YANG, John H. DODD
  • Orally Active Melanocortin Receptor-4 Compounds
    Publication number: 20220204450
    Abstract: A compound of the formula where R1, R2, R3, R4, R5, R6a, and R6b are as defined in the specification and claims, or an enantiomer, stereoisomer or diastereoisomer thereof, or a pharmaceutically acceptable salt thereof, and the use thereof in the treatment of diseases, disorders, syndromes and conditions responsive to modulation of a melanocortin receptor.
    Type: Application
    Filed: March 9, 2022
    Publication date: June 30, 2022
    Applicant: Palatin Technologies, Inc.
    Inventors: James Bullington, Axel Metzger, John H. Dodd
  • Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy
    Patent number: 11286280
    Abstract: Methods preventing, ameliorating or treating cytokine storm or inflammatory disease, indications, conditions and syndromes by administration of a therapeutically effective amount of a melanocortin-1 receptor-specific cyclic peptide or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 13, 2020
    Date of Patent: March 29, 2022
    Assignee: Palatin Technologies, Inc.
    Inventors: Wei Yang, Yi-Qun Shi
  • Melanocortin receptor-specific peptide with C-terminal naphthylalanine
    Patent number: 10711039
    Abstract: Melanocortin receptor-specific peptides with a C-terminal naphthylalanine of the formula: where R4, R7, R9, R11, R18, R20, R21a, R21b, R21c and R22 are as defined in the claims, compositions and formulations including the peptides of the foregoing formula or salts thereof, and methods of preventing, ameliorating or treating melanocortin receptor-mediated or responsive diseases, indications, conditions and syndromes.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: July 14, 2020
    Assignee: Palatin Technologies, Inc.
    Inventors: Wei Yang, Yi-Qun Shi
  • Therapies for obesity, diabetes and related indications
    Patent number: 10660939
    Abstract: The invention relates to methods, uses, compositions and formulations including a melanocortin receptor-4 agonist and a glucagon-like peptide-1 receptor agonist for treatment of obesity, diabetes, metabolic syndrome and related indications, diseases or disorders.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: May 26, 2020
    Assignee: Palatin Technologies, Inc.
    Inventors: Carl Spana, John H. Dodd, Marie Makhlina
  • Melanocortin receptor-specific peptides
    Patent number: 10632171
    Abstract: Melanocortin receptor-specific cyclic peptides of the formula where R1, R3, R4, R9 and R10 are as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: April 28, 2020
    Assignee: Palatin Technologies, Inc.
    Inventors: Yi-qun Shi, Shubh D Sharma, John H Dodd, Wei Yang, Xin Chen
  • Uses of bremelanotide in therapy for female sexual dysfunction
    Patent number: 10286034
    Abstract: Use of a subcutaneously administered dose of between about 1.25 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: May 14, 2019
    Assignee: Palatin Technologies, Inc.
    Inventors: Carl Spana, Robert Jordan, Jeffrey D. Edelson
  • Melanocortin receptor-specific peptides
    Patent number: 10179804
    Abstract: Melanocortin receptor-specific cyclic peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and z are as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: January 15, 2019
    Assignee: Palatin Technologies, Inc.
    Inventors: Yi-qun Shi, Shubh D. Sharma, John H. Dodd, Wei Yang
  • Melanocortin-1 receptor-specific linear peptides
    Patent number: 10106578
    Abstract: Melanocortin receptor-specific linear peptides of the formula Z-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Y??(VI) or a pharmaceutically acceptable salt thereof, where Z, Y, Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, and Xaa6 are as defined in the specification, compositions and formulations including peptides of the foregoing formula or salts thereof, and pharmaceutical compositions for preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: October 23, 2018
    Assignee: Palatin Technologies, Inc.
    Inventors: Wei Yang, Yi-Qun Shi
  • Melanocortin-1 receptor-specific cyclic hexapeptides
    Patent number: 10017539
    Abstract: Melanocortin receptor-specific cyclic hexapeptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the claims, compositions and formulations including the hexapeptides of the foregoing formula or salts thereof, and methods of preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: July 10, 2018
    Assignee: Palatin Technologies, Inc.
    Inventors: Wei Yang, Yi-Qun Shi
  • Uses of bremelanotide in therapy for female sexual dysfunction
    Patent number: 9700592
    Abstract: Use of a subcutaneously administered dose of between about 1.0 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: July 11, 2017
    Assignee: Palatin Technologies, Inc.
    Inventors: Carl Spana, Robert Jordan, Jeffrey D. Edelson
  • Melanocortin-1 receptor-specific linear peptides
    Patent number: 9580466
    Abstract: Melanocortin receptor-specific linear peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined in the specification, compositions and formulations including peptides of the foregoing formula or salts thereof, and pharmaceutical compositions for preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: February 28, 2017
    Assignee: Palatin Technologies, Inc.
    Inventors: Wei Yang, Yi-Qun Shi
  • Melanocortin receptor-specific heptapeptides
    Patent number: 9458201
    Abstract: Melanocortin receptor-specific cyclic heptapeptides of the formula Z-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Y??(II) or a pharmaceutically acceptable salt thereof, where Z, Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, Xaa6, Xaa7 and Y are as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: October 4, 2016
    Assignee: Palatin Technologies, Inc.
    Inventors: Yi-qun Shi, Shubh D. Sharma, John H. Dodd, Wei Yang
  • Melanocortin-1 receptor-specific cyclic peptides
    Patent number: 9447148
    Abstract: Melanocortin receptor-specific cyclic peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the specification, compositions and formulations including the peptides of the foregoing formula or salts thereof, and methods of preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: September 20, 2016
    Assignee: Palatin Technologies, Inc.
    Inventors: Wei Yang, Yi-Qun Shi
  • Uses of bremelanotide in therapy for female sexual dysfunction
    Patent number: 9352013
    Abstract: Use of a subcutaneously administered dose of between about 1.0 mg and 1.75 mg of bremelanotide or a pharmaceutically acceptable salt of bremelanotide for the treatment of female sexual dysfunction in women while reducing or minimizing undesirable side effects.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: May 31, 2016
    Assignee: Palatin Technologies, Inc.
    Inventors: Carl Spana, Robert Jordan, Jeffrey D. Edelson
  • Lactam-bridged melanocortin receptor-specific peptides
    Patent number: 9273098
    Abstract: Lactam-bridged melanocortin receptor-specific cyclic peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes, including obesity, modulation of feeding behavior, related metabolic syndrome, sexual dysfunction, male erectile dysfunction and female sexual dysfunction.
    Type: Grant
    Filed: December 6, 2011
    Date of Patent: March 1, 2016
    Assignee: Palatin Technologies, Inc.
    Inventors: Xin Chen, Wei Yang
  • Melanocortin-1 receptor-specific linear peptides
    Patent number: 8933194
    Abstract: Melanocortin receptor-specific linear peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 are as defined in the specification, compositions and formulations including peptides of the foregoing formula or salts thereof, and pharmaceutical compositions for preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: January 13, 2015
    Assignee: Palatin Technologies, Inc.
    Inventors: Wei Yang, Yi-Qun Shi
  • Melanocortin-1 receptor-specific cyclic peptides
    Patent number: 8877890
    Abstract: Melanocortin receptor-specific cyclic peptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the specification, compositions and formulations including the peptides of the foregoing formula or salts thereof, and methods of preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: November 4, 2014
    Assignee: Palatin Technologies, Inc.
    Inventors: Wei Yang, Yi-Qun Shi